Paralysis of Nematode Parasites

线虫寄生虫的麻痹

基本信息

  • 批准号:
    8811755
  • 负责人:
  • 金额:
    $ 44.25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-12-15 至 2018-11-30
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): Nematode infections are a major cause of human morbidity and contribute significantly to a loss of Disability Adjusted Life Years. More importantly, in many cases, such as filarial infection, effective chemotherapy is still not availabe. Perhaps less well appreciated, but equally important for human health, is the devastating economic impact of parasitic nematodes on livestock and plants, and new anthelmintic and drug targets are both desperately needed in all settings. Most anthelmintic in use against nematode infections act as agonists at key receptors and cause paralysis by interfering with muscle contraction and/or locomotion. The overall objective of this application is to promote the development of new anthelmintic that target locomotion to cause paralysis. We have characterized key monoamine receptors regulating locomotion using an innovative 'dual systems' approach that exploited the experimental advantages of the C. elegans and Ascaris suum models. Highlighting the utility of this approach, C. elegans molecular genetics was instrumental in isolating key receptor genes; bioinformatics approaches then identified corresponding parasitic nematode cDNAs, and ultimately, four key monoamine receptors were identified as promising possible anthelmintic targets. In the present study we will develop innovative anthelmintic drug screening strategies based on these receptors by characterizing their agonist sensitivities in heterologous cells, and expressing them in C. elegans, to create 'chimeric' nematodes to confirm orthodoxy and allow agonist screening under physiological conditions. We will establish the sites of action and physiological roles of these receptors in the locomotors circuitry of parasitic nematodes by direct functional localization and electrophysiological approaches. These studies will not only identify definitively key monoamine receptors regulating locomotion in parasitic nematodes, but because of the enormous diversity among nematodes, they will also highlight the potential differences between these two important model systems. Locomotion is critical to the survival of parasitic nematodes, and drugs that inhibit locomotion can successfully clear parasitic nematode infection. These studies will identify a wealth of potential novel molecular targets for drug discovery.
 描述(由申请人提供):线虫感染是人类发病率的主要原因,并显著导致残疾调整寿命年的损失。更重要的是,在许多情况下,例如丝虫感染,仍然无法获得有效的化疗。寄生线虫对家畜和植物的破坏性经济影响或许不太受重视,但对人类健康同样重要,而且在所有环境中都迫切需要新的驱虫剂和药物靶标。大多数用于治疗线虫感染的驱虫药作为关键受体的激动剂,通过干扰肌肉收缩和/或运动而导致瘫痪。这项应用的总体目标是促进以运动为靶点导致瘫痪的新驱虫剂的开发。我们利用线虫和猪蛔虫模型的实验优势,采用了一种创新的“双重系统”方法,表征了调节运动的关键单胺受体。线虫分子遗传学在分离关键受体基因方面发挥了重要作用,生物信息学方法随后确定了相应的寄生线虫cDNA,最终确定了四个关键的单胺受体作为有希望的驱虫靶标。在本研究中,我们将开发基于这些受体的创新的驱虫药筛选策略,通过在异源细胞中表征它们的激动剂敏感性,并在线虫中表达它们,以创建“嵌合”线虫来确认正统,并允许在生理条件下进行激动剂筛选。我们将确定这些受体的作用部位和生理作用。 用直接功能定位和电生理方法研究寄生线虫的运动回路。这些研究不仅将确定寄生线虫中调控运动的关键单胺受体,而且由于线虫之间的巨大多样性,它们也将突出这两个重要模式系统之间的潜在差异。运动对寄生线虫的生存至关重要,抑制运动的药物可以成功清除寄生线虫感染。这些研究将确定 为药物发现提供了大量潜在的新型分子靶点。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Richard Walter Komuniecki其他文献

Richard Walter Komuniecki的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Richard Walter Komuniecki', 18)}}的其他基金

Locomotion in Parasitic Nematodes
寄生线虫的运动
  • 批准号:
    7555907
  • 财政年份:
    2008
  • 资助金额:
    $ 44.25万
  • 项目类别:
Locomotion in Parasitic Nematodes
寄生线虫的运动
  • 批准号:
    8213392
  • 财政年份:
    2008
  • 资助金额:
    $ 44.25万
  • 项目类别:
Locomotion in Parasitic Nematodes
寄生线虫的运动
  • 批准号:
    8013610
  • 财政年份:
    2008
  • 资助金额:
    $ 44.25万
  • 项目类别:
Locomotion in Parasitic Nematodes
寄生线虫的运动
  • 批准号:
    7465046
  • 财政年份:
    2008
  • 资助金额:
    $ 44.25万
  • 项目类别:
Locomotion in Parasitic Nematodes
寄生线虫的运动
  • 批准号:
    7760892
  • 财政年份:
    2008
  • 资助金额:
    $ 44.25万
  • 项目类别:
REGULATION OF PHARYNGEAL PUMPING IN PARASITIC NEMATODES
寄生线虫咽泵的调节
  • 批准号:
    7177475
  • 财政年份:
    2005
  • 资助金额:
    $ 44.25万
  • 项目类别:
REGULATION OF PHARYNGEAL PUMPING IN PARASITIC NEMATODES
寄生线虫咽泵的调节
  • 批准号:
    7010320
  • 财政年份:
    2005
  • 资助金额:
    $ 44.25万
  • 项目类别:
REGULATION OF PHARYNGEAL PUMPING IN PARASITIC NEMATODES
寄生线虫咽泵的调节
  • 批准号:
    7559553
  • 财政年份:
    2005
  • 资助金额:
    $ 44.25万
  • 项目类别:
REGULATION OF PHARYNGEAL PUMPING IN PARASITIC NEMATODES
寄生线虫咽泵的调节
  • 批准号:
    7339642
  • 财政年份:
    2005
  • 资助金额:
    $ 44.25万
  • 项目类别:
REGULATION OF PHARYNGEAL PUMPING IN PARASITIC NEMATODES
寄生线虫咽泵的调节
  • 批准号:
    6865260
  • 财政年份:
    2005
  • 资助金额:
    $ 44.25万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 44.25万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 44.25万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 44.25万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 44.25万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 44.25万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 44.25万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 44.25万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 44.25万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 44.25万
  • 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
  • 批准号:
    23K05057
  • 财政年份:
    2023
  • 资助金额:
    $ 44.25万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了